Assertio Therapeutics (ASRT) Tops Q2 EPS by 20c

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.28, $0.20 better than the analyst estimate of $0.08. Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.63 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley turns cautious on freight stocks despite stronger cycle outlook
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO